Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
0 Wat vind je van dit boek? Geef jouw beoordeling. 0 0 0 0 0 Willen dit boek lezen 0 Lezen dit boek 0 Hebben dit boek gelezen 2 De Nederlandse Boekenbon is supporter van lezerscommunity Hebban
Clinical and Experimental Hepatology, Mar 2023 This is a preview of a remote PDF: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090989/pdf/ S. Giri, V. Jearth, V. Seth, H. Darak, S. Sundaram. , Clinical and Experimental Hepatology, 2023, pp. 57, Volume 9, Issue 1, DOI: 10.5114/ceh.2023.126077
343P Outcomes of good risk AML from a tertiary cancer centre: Is good always good? Background: Good risk AML is defined cytogenetically by the presence of good risk cytogenetics which include t(8;21), inv 16, t(16;16) and is characterized by a significantly better outcome following standard induction chemotherapy followed by consolidation with high dose cytarabine. Many studies have shown that the outcome of good risk AML can range from 60% to 80% depending on the series .
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
